Literature DB >> 8939705

Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells.

G Fenteany1, S L Schreiber.   

Abstract

BACKGROUND: Lactacystin inhibits cell proliferation and induces a distinctive, predominantly bipolar (two-neurite-bearing) morphology in Neuro 2A murine neuroblastoma cells. It binds with high specificity to the multicatalytic 20S proteasome and inhibits at least three of its peptidase activities (chymotrypsin-like, trypsin-like and peptidylglutamyl-peptide hydrolyzing), each at a different rate, without inhibiting other known proteases. The chymotrypsin-like and trypsin-like activities of the proteasome are inhibited most rapidly, and irreversibly. In an effort to determine which of the peptidase activities needs to be inhibited for neurite outgrowth to occur, we treated Neuro 2A cells with peptide aldehydes that selectively inhibit different proteasome activities.
RESULTS: Treatment with peptide aldehydes ending in a hydrophobic residue, all of which inhibit the chymotrypsin-like activity, results in a bipolar morphology in Neuro 2A cells, whereas treatment with a peptide aldehyde inhibitor of the trypsin-like activity does not lead to a detectable change in morphology. One of the inhibitors that induces neurite outgrowth has been previously shown to inhibit the chymotrypsin-like activity of the proteasome without inhibiting the other apparently distinct peptidase activities that cleave after neutral residues, the so-called 'branched chain amino acid preferring' (BrAAP) and 'small neutral amino acid preferring' (SNAAP) activities, or the peptidylglutamyl-peptide hydrolyzing (PGPH) activity.
CONCLUSIONS: The chymotrypsin-like activity appears to antagonize bipolar-type neurite outgrowth in Neuro 2A cells, while the trypsin-like, PGPH, BrAAP and SNAAP appear not to do so. Selective inhibition of a single peptidase activity, as opposed to general inhibition of the proteasome, appears sufficient to induce a specific cellular process. Selective inhibition might be useful in managing diseases where only one activity is involved without completely inhibiting the proteasome. It is also possible that endogenous regulators of the proteasome could affect cellular processes and that certain peptidase activities of the proteasome may have roles in specifying a given cell fate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8939705     DOI: 10.1016/s1074-5521(96)90179-9

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  5 in total

1.  Viability assays for cells in culture.

Authors:  Jessica M Posimo; Ajay S Unnithan; Amanda M Gleixner; Hailey J Choi; Yiran Jiang; Sree H Pulugulla; Rehana K Leak
Journal:  J Vis Exp       Date:  2014-01-20       Impact factor: 1.355

2.  Regulation of the neuronal proteasome by Zif268 (Egr1).

Authors:  Allan B James; Ann-Marie Conway; Brian J Morris
Journal:  J Neurosci       Date:  2006-02-01       Impact factor: 6.167

Review 3.  Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.

Authors:  H Yang; K R Landis-Piwowar; D Chen; V Milacic; Q P Dou
Journal:  Curr Protein Pept Sci       Date:  2008-06       Impact factor: 3.272

4.  Proteasome inhibitors which induce neurite outgrowth from PC12h cells cause different subcellular accumulations of multi-ubiquitin chains.

Authors:  R Ohtani-Kaneko; K Takada; M Iigo; M Hara; H Yokosawa; S Kawashima; K Ohkawa; K Hirata
Journal:  Neurochem Res       Date:  1998-11       Impact factor: 3.996

5.  Selective depletion of tumour suppressors Deleted in Colorectal Cancer (DCC) and neogenin by environmental and endogenous serine proteases: linking diet and cancer.

Authors:  Caroline M Forrest; Kara McNair; Maria C J Vincenten; L Gail Darlington; Trevor W Stone
Journal:  BMC Cancer       Date:  2016-10-06       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.